This website uses its own and third-party cookies. Some of these cookies are used to develop analytical statistics of visits to the webpage, others to manage advertising or even others are necessary for the correct management of the site. If you continue to browse or click in accept we consider you accept the conditions for their use. You can get more information, or learn how to change the settings in our cookies policy?
Versión Española Versión Mexicana Ibercampus English Version Version française Versione italiana

13/12/2019  
    Ibercampus  | Editorial Board | Who we are | Ideology | Contact | Advertising rates | Subscription | RSS RSS
Policies
Inclusion policies
R&D
Employment
Economics
Culture
Green strategies
Health
Society and consumer
Sports
Debates
Interviews
Education
Grants & internships
Training
Trends
Enterprises & CSR
 Enterprises & CSR
ACNUR
AEGON
AIR LIQUIDE
ALCATEL-LUCENT
ALLIANZ
ARCELORMITTAL
ASIFIN
ASSICURAZIONI GENERALI
AXA
BANCO SANTANDER
BASF
BAYER
BBVA
BNP PARIBAS
CARREFOUR
DAIMLER AG
DEUTSCHE BANK
DEUTSCHE BÖRSE
DEUTSCHE TELEKOM
E.ON
ENEL
ENI
FORTIS
FRANCE TÉLÉCOM
GROUPE DANONE
IBERDROLA
INDITEX
ING GROUP
INTESA SANPAOLO
L'ORÉAL
LVMH
MUNICH RE
NOKIA
PHILIPS
RENAULT
REPSOL YPF
RWE
SAINT GOBAIN
SANOFI-AVENTIS
SAP AG
SCHNEIDER ELECTRIC
SIEMENS AG
SOCIÉTÉ GÉNÉRALE
SUEZ
TELECOM ITALIA
TELEFÓNICA
TOTAL S.A.
UNICREDIT
UNILEVER
VINCI
VIVENDI
VOLKSWAGEN

R&D

New methodology developed to monitor patients with glioblastoma

HTS methodology. / Lena Kay/UPV

Seven European hospitals have validated a new methodology developed at Universitat Politècnica de València (UPV, Spain) to monitor patients with glioblastoma. This methodology helps medical doctors know the patients´ situation with greater precision; it allows them to obtain several vascular biomarkers directly linked to their survival
Ibercampus / Sinc 28/11/2019 Send to a friend
Comparte esta noticia en TwitterFacebookTwitterdel.icio.usYahooRSS
Glioblastoma (GBM) is the most aggressive brain tumor in adults. Now, it can be treated with neurosurgery, radiotherapy and chemotherapy. Still, the median life expectancy of patients affected with this pathology is no longer than 15 months. Within this context, researchers at the Universitat Politècnica de València (UPV) have been working for 15 years in new biomedical tools that can help to the follow-up of this tumor. The last of them is ONCOHabitats, a platform that allows medical doctors to know the patient´s real situation with greater precision according to the vascularity of different areas of the tumor. "These results consolidate the effort of almost 15 years working in this field. The potential application of this tool has been now validated by seven European hospitals with the first multicenter clinical study promoted by the Universitat Politècnica de València," says Juan Miguel García-Gómez, coordinator of the Biomedical Data Science Lab-ITACA of UPV. The seven centers that have taken part in the study are the Hospital Universitario de La Ribera, the Hospital de Manises, the Hospital Clínic in Barcelona, the Hospital Universitario Vall d´Hebrón, the Azienda Ospedaliero-Universitaria in Parma (Italy), the Centre Hospitalier Universitaire in Liège (Belgium) and the Oslo University Hospital (Norway). The results have been published in the Journal of Magnetic Resonance Imaging. Key finding for medical prognosis The methodology developed by the team of UPV researchers helps to discover new areas in the tumor and makes the monitoring of the patient´s evolution easier, thanks to new biomarkers. The key lies in the analysis of five types of Magnetic Resonance Images – four morphological MRIs and one perfusion MRI. According to the researchers at UPV´s Biomedical Data Science Lab-ITACA, from these Magnetic Resonance Images and our methodology, it is possible to establish separated areas inside the tumor and the edema. From them, ONCOHabitats allows medical doctors to obtain vascular biomarkers—brain blood volume—in the areas of the active tumor and Infiltrated Peripheral Edema that are directly linked to the patients´ survival, before they undergo surgery. Until now, most studies have focused on studying the active tumor. However, we have found a new area of great interest, the Infiltrated Peripheral Edema. We have seen that the biomarkers obtained in this area provide very relevant information on the aggressiveness of the tumor and therefore, on the prognosis and follow-up of the patient. Within the study, researchers worked with 184 patients´ MRIs from the seven centers that took part. The study has proved the robustness of calculating biomarkers using the methodology developed by UPV compared to the variability of applying Magnetic Resonance Images acquisition protocols. "We have proved in seven hospitals that our methodology is reliable and robust, independently of the variations that can appear when acquiring and processing MRIs and, ultimately, obtaining the biomarkers. These results endorse its viability for the implantation in the clinical practice; the next step is to biologically characterize what it is discovered in the image, and we are already working on it," explains María del Mar Álvarez-Torres, researcher at the Biomedical Data Science Lab-ITACA of the Universitat Politècnica de València. Spanish representative As a result of this study, the team of the Biomedical Data Science Lab-ITACA of the Universitat Politècnica de València was selected to represent Spain in the European net GliMR Cost Action for studying glial tumors using MRI. "In addition to clinical doctors, ONCOhabitats can be highly useful for researchers studying glial tumors with other Magnetic Resonance sequences," concludes Juan Miguel García-Gómez.
Other issues R&D
China, Germany, Japan, Korea and the United States dominate global innovation - WIPO report 2019
Scientists find a place on Earth where there is no life
The embryonic origin of the Cyclops eye
Graphene activates immune cells helping bone regeneration in mice
Jurassic dinosaurs could have been dispersed between Africa and Europe 145 years ago
China´s Chang´e-4 probe lands on the moon
Artificial intelligence for studying the ancient human populations of Patagonia.
Chinese and European scientists propose 28 complementary colours
EU-wide rules for safety of drones approved by European Parliament
EU has more digital specialists than before but skills gaps remain

Subscribe free to our newsletter
Vanity Fea
The Virtual World We Inhabit
José Ángel García Landa
We can all be leaders
VIDEOCOMMUTING A NEW ORGANIZATIONAL REALITY THAT POSITIVELY IMPACTS EMPLOYEES
Mar Souto Romero
Financial inclusion
Financial Education For All!
Carlos Trias
Brusselian Lights
European elections (I): which words are more used in the European political manifestos?
Raúl Muriel Carrasco
Humor and Political Communication
Comisión de Arbitraje, Quejas y Deontología (Spain) (3) You can´t be too careful
Felicísimo Valbuena
Want your own blog? Want to be read by universities?
Find out here
Books
"Tthe study of human behaviour was political from the beginning"
The EU "An Obituary"
Startup Cities "Why Only a Few Cities Dominate the Global Startup Scene"
Blockchain Revolution "How the Technology Behind Bitcoin and Cryptocurrency Is Changing the World "
Doughnut Economics "Seven Ways to Think Like a 21st-Century Economist "
The People vs Tech "How the Internet Is Killing Democracy"
Theses and dissertations
1 The Virtual World We Inhabit
2 Squid pigments could be used in food and health for their antioxidant and antimicrobial properties
3 Health in the EU: shift to prevention and primary care is the most important trend across countries
4 "Tthe study of human behaviour was political from the beginning"
5 New methodology developed to monitor patients with glioblastoma
6 China, Germany, Japan, Korea and the United States dominate global innovation - WIPO report 2019
7 Graphene activates immune cells helping bone regeneration in mice
8 Scientists find a place on Earth where there is no life
9 Education 4.0: Beware the dark side of university restructuring
10 The embryonic origin of the Cyclops eye
Legal Advise | Privacy Policy | Editorial Board | Who we are | Ideology | Contact | Advertising rates | RSS RSS